INHIBITEX MOVES FORWARD WITH BLA FOR VERONATE
Inhibitex has initiated the rolling submission of its biologics license
application (BLA) with the FDA for the use of Veronate to prevent hospital-associated
infections in infants weighing between 500 g and 1,250 g at birth.
The rolling submission is an FDA provision, available to drug candidates that have received Fast Track designation, which allows for completed sections of a BLA to be submitted on an ongoing basis.